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Abstract 
The specific aim of this work was to prepare mucoadhesive patches containing 
tetracycline hydrochloride and carvacrol in an attempt to develop a novel oral 
drug delivery system for the treatment of mouth infections. The bilayered 
patches were prepared using ethyl cellulose as a backing layer and carbopol 
934 as a matrix mucoadhesive layer. Patches were prepared with different 
loading amounts of tetracycline hydrochloride and carvacrol. The antimicrobial 
activity was assessed for the prepared patches using the disc-diffusion method 
against the yeast Candida albicans and five bacterial strains, including 
Pseudomonas aeruginosa,  Escherichia coli,  Bacillus  cereus,  Staphylococcus 
aureus, and Bacillus bronchispti. In this work, we highlighted the possibility of 
occurrence of a synergistic action between carvacrol and tetracycline. The best 
formulation was selected based on microbiological tests, drug release, ex-vivo 
mucoadhesive performance, and swelling index. Physical characteristics of the 
selected formulations were determined. These included pH, patch thickness, 
weight uniformity, content uniformity, folding endurance, and patch stability. 
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Introduction 
Oral diseases are a health problem in immuno-suppressed patients around the world since 
the oral cavity provides a diverse environment for colonization by a wide variety of 
microorganisms [1–6]. Most of mouth infections are mainly due to candidiasis and bacterial 
infections. It has been reported that more than 300 bacterial species have been identified 
in the periodontal pockets [6]. 
Tetracyclines are a group of broad-spectrum antibiotics, which were introduced into clinical 
practice in the late 1940s [7–11]. They are bacteriostatic antibiotics which interfere with the 
bacterial protein synthesis. A further mechanism may be associated with the ability of 
tetracyclines to scavenge reactive oxygen radicals produced by neutrophils which will 
prevent further tissue destruction. Thus, tetracyclines may have general antiproteolytic 
properties. It is now well established that tetracyclines have anticollagenase properties 
unrelated to their antibacterial activity [11]. Tetracycline HCl has a broad spectrum activity 
inhibiting both Gram negative and Gram positive organisms, including the beta-lactamase-
producing strains against which penicillin is ineffective. Tetracycline HCl has been shown 
to be effective against many of the common periodontopathic bacteria, in particular, 
Prevotella intermedia and Porphyromonas gingivalis [10].  
One of the major concerns about antibiotic usage, particularly in long-term low dosage 
regimes, is that bacteria may develop resistance to the antibiotic. Microorganisms can 
develop resistance after exposure to sub-inhibitory concentrations of antibiotics [12]. 
Recently, a combination of two or more antibiotics has been recognized as an important 
method for, at least, delaying the emergence of bacterial resistance [11]. Besides, 
antibiotic combinations may also produce desirable synergistic effects in the treatment of 
infections [11, 12].  
Essential oils, such as oregano oil, have been shown to be useful as antimicrobial and 
antifungal agents; competing pharmaceutical antibiotics such as streptomycin and 
penicillin and antifungal agents such as nystatin and amphotericin have been proved to be 
effective in their ability to eliminate microbes [12]. All this has been accomplished without 
promoting the development of drug-resistant strains and other problems often attributed to 
the use of standard antibiotics. Carvacrol, 5-isopropyl-2-methylphenol, has been identified 
as the chief constituent of oregano oil's extraordinary properties. It is generally recognized 
as a food additive and a flavoring agent [12, 13]. Essential oils containing carvacrol are 
biostatic and biocidal against many bacterial strains, yeasts, and fungi in laboratory media 
and have consequently attracted considerable research attention as potential food 
preservatives. Carvacrol has also been shown to inactivate microorganisms in biofilms or 
stainless steel surfaces [13]. It has anti-fungal activity against Candida species. The 
biocidal mode of action of carvacrol on bacteria is similar to that of other phenolic 
compounds where it increases the microbial cell membrane permeability to protons and 
potassium ions. This will induce cell membrane damage. In addition, carvacrol was also 
shown to rapidly desensitize pain receptors [12]. 
The consequent need for local drug delivery has been recognized since many years. To 
date, a great number of local drug delivery systems and devices have been proposed for 
oral and dental applications, including fibers, strips, films, gels, sponges, microparticles, 
etc [12–19]. It is speculated that a higher mucoadhesive strength of the delivery system   Preparation of Mucoadhesive Oral Patches Containing Tetracycline Hydrochloride and Carvacrol … 199 
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will lead to prolonged retention of the device in the oral cavity and increased absorption 
across mucosal tissues [20–24]. Most of the previously formulated drug delivery systems 
involved treatment of bacterial infections alone or candidiasis.  
The main objective of this study was to develop an oral mucoadhesive controlled-release 
delivery system containing tetracycline HCl and carvacrol. This system is intended for local 
treatment of both oral candidiasis and bacterial infections. Selection of tetracycline and 
carvacrol as active ingredients in the proposed oral patches was based on the expected 
complementary action from both of them.  
Experimental 
Materials 
Tetracycline HCl was kindly provided by Dar Al-Dawaa Company [Jordan]. Carbopol 934 
Q.C no. 1001333 and glycerol were obtained from Scharlau Chemie [Spain]. Carvacrol 
and ethyl cellulose CAS number 9004-57-3 were obtained from Sigma Chemical Co. 
[USA]. The water used throughout all the experiments was HPLC grade and was obtained 
from Acros Organics [Belgium]. All reagents were of pharmaceutical grade and used as 
supplied without further treatment. 
Microorganisms 
Microorganisms were obtained from Dar Al-Dawaa Company [Jordan]. Two strains of 
gram-negative bacteria Escherichia coli [ATCC 8739] and Pseudomonas aeruginosa 
[ATCC 9027]; three strains of gram-positive bacteria Staphylococcus aureus [ATCC 6538], 
Bacillus cereus [ATCC 14579], and Bacillus bronchispti [ATCC 4617]; and yeast Candida 
albicans [ATCC 10231] were used. The cultures of the bacteria were maintained in their 
appropriate agar plates at 4°C throughout the study. 
Preparation of the bilayered mucoadhesive patches 
Bilaminated films were produced by a casting/solvent evaporation technique using 
different combinations of polymers and drugs. The backing membrane was prepared by 
dissolving ethyl cellulose [5%] in chloroform with 1.35 g of propylene glycol [30% w/w of 
polymer content] as a plasticizer. The plasticized ethyl cellulose solution was poured into a 
10 cm
2 glass mould on a leveled surface and the solvent was allowed to evaporate at 
ambient temperature. 
The mucoadhesive layer was prepared using carbopol 934 as the polymer-forming matrix. 
Two grams of carbopol 934 were soaked in 70 ml water for 24 h, after which 30 ml of 
ethanol was added; glycerol at a concentration of 25% w/w of polymer content was added 
as a plasticizer. The dispersion was stirred at 150 rpm using a mechanical stirrer for 3 h. 
Various loading amounts of tetracycline HCl and carvacrol were added to 20 ml of the 
polymer dispersion to obtain various formulations as shown in Table 1. The pH of the 
resultant dispersion was measured, and it had an average value of 6.5±0.6. The 
plasticized polymeric solution was poured into a glass mould containing the backing 
membrane and oven-dried at 30 °C for 96 h. The dried films were peeled from the glass 
mould and cut into circular shapes of small size. They were kept at 25 °C in a desiccator 
containing a saturated solution of sodium dichromate [Na2Cr2O7], which provided an 200  R. M. Obaidat et al.:  
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environmental condition of 55% relative humidity [RH] for at least 2 days before testing. 
Patches with any imperfections, entrapped air, or mean thickness variations of ± 5% were 
excluded from further analysis and use. 
Tab. 1.   Tetracycline HCl and carvacrol contents of the prepared patches 
Formula Tetracycline  HCl 
[g/10 cm
2] 
Carvacrol 
[mg/10 cm
2] 
F1  0 0 
F2  0 0.50 
F3  0 0.80 
F4  0 1.10 
F5  0 1.40 
F6  0 1.70 
F7  0 2.00 
F8  0.01 0 
F9  0.02 0 
F10  0.03 0 
F11  0.04 0 
F12  0.05 0 
F13  0.06 0 
F14  0.01 1.10 
F15  0.02 1.10 
F16  0.03 1.10 
F17  0.04 1.10 
F18  0.05 1.10 
F19  0.06 1.10 
 
Antimicrobial activity 
Screening of the prepared patches for antimicrobial activity was performed according to 
the disc diffusion method [24, 25]. It was performed using an 18-h culture at 37 °C in 10 ml 
of Mueller-Hinton broth [Oxoid, England] with sterile saline solution. The disc diffusion test 
was performed on Mueller-Hinton agar. Plates were cultured with appropriate test 
organisms overnight. For C. albicans, Sabouraud dextrose agar and Sabouraud dextrose 
broth were used. On the following day, three to five freshly grown colonies of bacterial 
strains were inoculated in 20 ml of Mueller-Hinton medium in a shaking water bath for  
4–6 h until a turbidity of 0.5 McFarland 1 × 10
8 colony forming unit [CFU/ml] was reached. 
Final inocula were adjusted to 5 × 10
5 CFU/ml. The inoculum [200 µl] from the final inocula 
was seeded onto the agar plate and uniformly spread with a sterilized cotton spreader over 
the surface. Discs of diameter 5 mm from each prepared films were attached to the 
product and deposited on Mueller-Hinton agar plates, except for C. albicans which was 
deposited on Sabouraud dextrose agar plates. The plates [prepared in triplicate for each 
strain] were then incubated at 37 °C for 24 h and the inhibition zones were measured after 
24 h for bacteria and 48 h for the fungus C. albicans [26]. Standard 5-mm tetracycline 
antibiotic discs [30 μg of tetracycline HCl/disc] were used as positive controls. Each film   Preparation of Mucoadhesive Oral Patches Containing Tetracycline Hydrochloride and Carvacrol … 201 
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was cut into discs of similar sizes. Discs [5 mm] from films without active ingredients were 
also used as negative control. 
In vitro drug release 
In vitro release of tetracycline HCl from the matrices through dialysis membrane was 
investigated using Franz-type diffusion cells with an effective diffusion area of 2.3 cm
2. A 
quantity of 15 ml of pH 7 phosphate buffer solution maintained at 37 °C and stirred at 100 
rpm was used as the receptor medium. The matrices [donor phase] were placed in contact 
with the dialysis membrane such that the backing layer faced the donor compartment and 
the adhesive film faced the receiver compartment fastened with an O-ring. At 
predetermined time intervals, 3-ml samples of the receiving phase were withdrawn for 
analysis and replaced with an equal volume of fresh buffer to maintain sink conditions. The 
amount of tetracycline HCl and carvacrol released was determined at 275 nm and 283 nm 
using a UV spectrophotometer [Cavy 1E Varian, USA]. Method of analysis was spectra-
first derivative method [27]. The method was validated and each release test was 
performed for a minimum of three times. UV-scan of placebo solution showed no absorbance 
at the analytical wavelength. 
Ex-vivo mucoadhesive force 
The mucoadhesive strength was determined by measuring the force of detachment or the 
force of adhesion and the ex-vivo adhesion time. These are the most frequently studied 
parameters for determination of adhesive properties.  
 
Fig. 1.  Schematic of the two-arm balance used in the assessment of the bioadhesion 
of the films 
The two-arm balance method reported by Parodi [26] with minor modifications was used to 
assess the bioadhesiveness of the films. Fresh rabbit buccal mucosa section [2×2 cm and 
2 mm thick] was fixed at the bottom of a smaller beaker placed in a larger beaker 
[Figure 1]. Krebs solution was added to the larger beaker up to the upper surface of the 
mucosa. The patch was attached to the upper clamp and the platform was slowly raised 
until the patch surface came in contact with mucosa. Two minutes of contact time was 
found to give optimum mucoadhesive strength. Further increase in contact time did not 
affect the mucoadhesive strength, whereas decreased contact time resulted in less 
mucoadhesive strength resulting from insufficient time for entanglement of polymer chains 202  R. M. Obaidat et al.:  
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with mucin. After a preload time of 5 minutes, a weight [g] was added to the second arm of 
the balance until the film was detached from the buccal mucosa. The weight [g] required 
for the detachment was recorded. The method was validated and the average values were 
reported after triplicate experiments. 
Measurement of mucoadhesion time 
The mucoadhesive performance of the buccal patches was evaluated using rabbit buccal 
mucosa tissue [2×2 cm and 2 mm thick]. The time taken for the film to detach from the 
mucosal section in a well-stirred beaker was used to assess the mucoadhesive 
performance. The fresh cut tissue was fixed to the side of the beaker with glue. Before 
addition of the buffer, the films were attached to buccal mucosal tissue by applying light 
force [approximately 0.5 N] for 20 sec. The beaker was then filled with 800 ml phosphate 
buffer and kept at a temperature of 37 °C. A stirring rate of 150 rpm was maintained to 
simulate the buccal and saliva movement. The time for the film to detach from the mucosal 
tissue was recorded up to 12 h. The average values were reported after repeating the 
experiments three times. 
Percent swelling 
Patches were weighed individually [designated as W1] and placed separately in a test tube 
filled with simulated saliva [2.38 g Na2HPO4, 0.19 g KH2PO4, and 8 g NaCl per liter of 
distilled water adjusted with phosphoric acid to pH 6.8] incubated at 37 ± 0.5 °C and 
examined for any physical changes. After 2 h, patches were removed from the test tube 
and excess surface water was removed carefully using filter paper. The swollen patches 
were then reweighed [W2] and the swelling index [%] calculated using the following 
equation: 
Eq. 1.  100
1
) 1 2 (
  [%] Index    Swelling ×
−
=
w
w w
 
The experiments are run in triplicates. 
Physical characteristics of the patches 
Folding endurance 
The folding endurance of the patches was determined by repeatedly folding a patch at the 
same place until it broke or was folded up to 250 times without breaking. 
Surface pH of the films 
For determination of the surface pH, three films from each patch were allowed to swell by 
keeping them in contact with 1 ml of distilled water for 2 h at room temperature. The pH 
was recorded by placing the electrode in contact with the surface of the patch and allowing 
it to equilibrate for 1 minute. 
Content uniformity, thickness, weight uniformity, and stability 
Drug content uniformity was determined by dissolving each patch in 30 ml of ethyl alcohol 
at 37 °C temperature and filtering through a 0.45 μm membrane filter [Millipore, USA]. The   Preparation of Mucoadhesive Oral Patches Containing Tetracycline Hydrochloride and Carvacrol … 203 
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filtrate was evaporated and the residue was dissolved in 100 ml of phosphate buffer 
[pH 6.8]. After 24 h, 5 ml solution was withdrawn and diluted with phosphate buffer [pH 
6.8] up to 20 ml, filtered through a 0.45 μm membrane filter and analyzed at 275 and 283 
nm for tetracycline and carvacrol content. 
The thickness of the selected patches was measured using a screw gauge. The weight 
variation of the patches was measured by weighing random pieces of patches of identical 
size. Thickness and weight variation measurement were obtained from six different areas 
in the patches including the edges and the middle parts. 
Stability testing of the prepared patches was performed by keeping the patches in glass 
Petri dishes lined with aluminum foil and stored in desiccators at 25 °C temperature and 
55% RH for 6 months. Changes in appearance and drug content of the stored patches 
were investigated at the end of the storage period. 
Readings from all the previous experiments were performed in triplicate and the average 
values were reported. 
Results and Discussion 
Antimicrobial activity 
Table 2 summarizes the antimicrobial activity of the patches against Candida albicans, 
Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Bacillus cereus, and 
Bacillus bronchispti.  The antimicrobial activity was assessed using the disc diffusion 
method and the mean inhibition zone diameters [MIDs] were recorded. Comparison was 
made with standard tetracycline disc and the effective MID was considered to be higher 
than 15 mm. The standard tetracycline disc showed activity against  Staphylococcus 
aureus [MID = 30 mm], Bacillus cereus [MID = 20 mm], Bacillus bronchispti [MID = 15 
mm], and Escherichia coli [MID = 15 mm]. 
The results showed that discs containing carvacrol alone [F2–F7] showed excellent activity 
against Candida albicans in amounts ≥40 μg/disc [F3], while discs containing tetracycline 
alone [F8–F13] did not show any activity against this microorganism [MID = zero]. 
However, either tetracycline alone or carvacrol alone was effective against Staphylococcus 
aureus and both of them did not show any activity against Pseudomonas aeruginosa [MID 
< 10 mm]. Tetracycline alone was very effective against Bacillus  cereus and  Bacillus 
bronchispti [MID values ranges from 15 to 20 mm] while carvacrol alone was not effective 
[MID < 12 mm]. Formulations containing tetracycline were all effective against Escherichia 
Coli [MID = 15 mm] while carvacrol was effective in amounts ≥ 85 μg/disc.  
Results for formulations containing tetracycline and carvacrol [F14–F19] showed that they 
were all effective against all tested microbes. Activity of these formulations against 
Pseudomonas aeruginosa was excellent and MID values ranged from 15 to 20 mm. These 
results indicate a synergistic action between tetracycline and carvacrol since both of them 
were separately ineffective against Pseudomonas aeruginosa. Also, their inhibition 
efficiency increased [MID > 30 mm] against Bacillus  cereus when they were used in 
combination which also indicates a synergistic effect. 
 204  R. M. Obaidat et al.:  
Sci Pharm. 2011; 79: 197–212 
Tab. 2.   Mean inhibition zone diameters of the prepared patches obtained on colonies of 
the microorganisms under study. 
Mean inhibition zone diameter (MID) [mm] 
Formula  Candida 
albicans 
Staph. 
aureus 
Pseud. 
aeruginosa 
Bacillus 
Cereus 
Bacillus 
Bronchis. 
Escher. 
Coli 
Std. tetra-
cycline disc  0 30  0  20  15  15 
F1  0 0  0  0  0  0 
F2  <10 0  <10  <10 <10 <10 
F3  20 15  <10  <10 <10 <10 
F4  >30 15  <10  <10  <10  <10 
F5  >30 15  <10  <10  <10  <10 
F6  >30 >30  <10  12  <10  15 
F7  >30 >30  <10  12  <10  15 
F8  0 >30  0  15  <15 <15 
F9  0 >30  0  15  15  15 
F10  0 >30  0  20  15  15 
F11  0 >30  0  20  20  15 
F12  0 >30  0  20  20  15 
F13  0 >30  0  20  20  15 
F14  >30 >30  15  >30  >30  23 
F15  >30 >30  15  >30  >30  25 
F16  >30 >30  20  >30  >30  25 
F17  >30 >30  20  >30  >30  25 
F18  >30 >30  20  >30  >30  25 
F19  >30 >30  25  >30  >30  25 
 
It is expected that the synergistic effect is due to enhancement of the permeability of 
tetracycline through the bacterial cell wall. This is due to the fact that one of the proposed 
mechanisms for the development of bacterial resistance against tetracycline might be due 
to decreased antibiotic influx through the bacterial cell wall [10]. On the basis of these 
results, the best formulations were those containing both tetracycline and carvacrol in 
combination [F14–F19]. 
In vitro drug release 
Figure 2 illustrates the percent tetracycline release profiles from the various patches   
[F14–F19]. These patches contain various combinations of tetracycline and a constant 
amount of carvacrol. It can be clearly seen that in all patches the percent released 
decreased with time. This could be due to the extensive swelling of the polymers creating 
a thick gel barrier, thus making drug diffusion to be slower with time. The slowest release 
is observed in the formulation containing the lowest concentration of tetracycline [F14]. 
Patches with higher loading doses of tetracycline showed fast release; however, patches 
with lower loading doses resulted in a sustained near zero-order release. This could be 
explained due to high water solubility of tetracycline HCl, which increased the swelling of 
the polymer and facilitated drug diffusion. As shown in Figure 2, patches F14–F16 
demonstrated sustained release of tetracycline for more than 6 h.   Preparation of Mucoadhesive Oral Patches Containing Tetracycline Hydrochloride and Carvacrol … 205 
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Fig. 2.   Release profiles of tetracycline HCl from patches F14-F19 in Franz diffusion cell 
at 37 °C and pH 7 [n =3]. 
 
Fig. 3.   Release profiles of carvacrol from patches F14–F19 in Franz diffusion cell at 
37 °C and pH 7 [n =3]. 
The release profile for carvacrol is shown in Figure 3. All the three formulas showed 
sustained release effect for carvacrol. It appears that there is no significant difference 
between the release profile for the various formulas; although increase in tetracycline 
concentration caused a slight increase in the release rate as can be observed in F19.  206  R. M. Obaidat et al.:  
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The release mechanism of the drug from the patches was investigated using the 
Korsemeyer-Peppas equation [29] 
Eq. 2. 
n t t k
M
M
⋅ =
∝
 
where  Mt/M∞ is the fractional release of the drug; t  denotes the release time; K  is a 
constant incorporating structural and geometric characteristics of the controlled release 
device; and n is the release exponent, indicative of the drug release mechanism. A linear 
form of this equation is  
Eq. 3.  () ( ) t Log n k Log
M
M
Log
t + = ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
∝
 
Tab. 3.   Summary of the physical characteristics of patches F14–F19. 
Release kinetic 
parameters  Patch 
Tetracycline  
HCl  Carvacrol
pH 
[±STD]
Content 
uniformity [%]
[±STD] 
Thickness 
[mm] 
[±STD] 
Weight 
variation
[mg] 
[±STD] 
F14 
n = 0.75 
K= 0.29 
R
2 = 0.99 
n = 0.85 
K= 0.76 
R
2 = 0.97 
6.4 
[±0.3] 
98% 
[±0.6] 
0.16 
[±0.02] 
0.05 
[±0.01] 
F15 
n = 0.74 
K = 0.21 
R
2 = 0.99 
n = 0.84 
K= 0.78 
R
2 = 0.97 
6.3 
[±0.4] 
99% 
[±0.5] 
0.15 
[±0.02] 
0.05 
[±0.01] 
F16 
n = 0.54 
K = 0.30 
R
2 = 0.99 
n = 0.82 
K= 0.72 
R
2 = 0.98 
6.5 
[±0.3] 
98% 
[±0.7] 
0.15 
[±0.01] 
0.05 
[±0.01] 
F17 
n = 0.51 
K = 0.33 
R
2 = 0.99 
n = 0.81 
K= 0.71 
R
2 = 0.97 
6.1 
[±0.7] 
100% 
[±0.9] 
0.15 
[±0.01] 
0.04 
[±0.01] 
F18 
n = 0.51 
K = 0.37 
R
2 = 0.99 
n = 0.74 
K= 0.65 
R
2 = 0.98 
6.3 
[±0.5] 
99% 
[±0.8] 
0.15 
[±0.01] 
0.05 
[±0.01] 
F19 
n = 0.50 
K = 0.41 
R
2 = 0.99 
n = 0.72 
K= 0.63 
R
2 = 0.98 
6.3 
[±0.5] 
99% 
[±0.7] 
0.16 
[±0.01] 
0.05 
[±0.01] 
 
Kinetic parameters are obtained from a plot of Log [Mt/M∞] versus Log [t], where n 
represents the slope and log [K] represents the intercept. In systems which could swell, 
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rate. When the liquid diffusion rate is slower than the relaxation rate of the polymeric 
chains, the diffusion is Fickian and n = 0.45. If 0.45 < n < 0.89; it indicates anomalous or 
non-Fickian mechanism. This indicates that liquid diffusion rate and polymer relaxation 
rate are of the same order of magnitude. Whereas when the relaxation process is very 
slow compared with the diffusion, case II transport occurs and n ≥ 0.89. This indicates that 
the release mechanism involves polymer erosion.  
Kinetic parameters for both tetracycline HCl and carvacrol obtained for patches F14–F19 
according to this equation are presented in Table 3. The diffusion exponent [n] for 
tetracycline HCl ranged from 0.50 to 0.75, while for carvacrol it ranged from 0.72 to 0.85. 
The correlation coefficient (r
2) was in the range of 0.97–0.99 for various formulations. This 
is an indication of anomalous, or non-Fickian, release mechanism.  
Ex-vivo mucoadhesive force 
Figure 4 shows the ex-vivo mucoadhesion force for the various patches prepared. The 
maximum bioadhesion force was observed for carbopol 934 [F1]. A possibility of hydrogen 
bonding between carboxylic groups of the polymer with the sugar residues in 
oligosaccharide chains in the mucus membranes, resulting in the formation of a 
strengthened network between the polymer and mucus membranes. Earlier work with 
carbopol 934 polymer has clearly indicated that the presence of carboxyl groups   
(58%–68%) in its structure contributes to its strong bioadhesion [16].  
 
Fig. 4.   Ex-vivo mucoadhesion force of the patches. The average values are presented 
± STD. 
Addition of carvacrol alone to the carbopol 934 polymer [F2–F7]; resulted in reduced 
bioadhesion. This could be because of chemical interaction between carvacrol and 
carbopol 934. This in turn decreases the possibility of interaction between the polymer and 208  R. M. Obaidat et al.:  
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the sugar residues in oligosaccharides chains in the mucus membranes and further 
decreasing polymer mucoadhesion. Figure 4 also illustrates that tetracycline addition   
[F8–F13] to the carbopol 934 polymer resulted in significant reduction in bioadhesion. This 
could be explained by the formation of hydrogen bonding between tetracycline and the 
polymer. In the rest of the formulations [F14–F19], an increase in the bioadhesion strength 
in the patches containing both tetracycline HCl and carvacrol was noted. This could be 
explained by possibility of hydrogen and π-π bonding between the phenolic hydroxyl 
groups of carvacrol with tetracycline, thus resulting in the polymer’s availability for 
interaction and adhesion to the mucus membranes. A previous study proved that addition 
of drugs that could form hydrogen bonds with the hydrophilic groups of the polymer is 
expected to decrease the bioadhesive force of the polymer [28]. According to this study, 
addition of a third component able to form hydrogen bonds with the drug is expected to 
free the bioadhesive polymeric chains and thereby enabling the polymer to retain its 
bioadhesive properties with the mucus membranes. This needs further study. 
The bioadhesive strength exhibited by the films was satisfactory in maintaining them in the 
oral cavity. This aspect was further confirmed by measurement of mucoadhesive time. 
During mucoadhesive time studies, none of the patches was dropped from the buccal 
tissue within 12 h of experiment time. 
Water uptake [swelling index] 
Hydration is required for a mucoadhesive polymer to expand and create a proper 
macromolecular mesh of sufficient size and also to induce mobility in the polymer chains in 
order to enhance the interpenetration process between the polymer and mucin. Polymer 
swelling permits a mechanical entanglement by exposing the bioadhesive sites for 
hydrogen bonding and/or electrostatic interaction between the polymer and the mucus 
network. However, a critical degree of hydration of the mucoadhesive polymer exists 
where optimum swelling and bioadhesion occurs. 
Figure 5 summarizes the swelling index values for the patches. Swelling behavior of 
carbopol 934 is attributed to the uncharged COOH group that is hydrated by forming 
hydrogen bonds with water, thus extending the polymer chains. Carbopol 934 polymers 
exhibit very good water sorption properties where they swell in water up to 1000 times 
their original volume and 10 times their original diameter to form a gel when exposed to a 
pH environment above 4 to 6. Because the pKa of these polymers is 6.0 to 6.5, the 
carboxylate moiety on the polymer backbone ionizes, resulting in repulsion between the 
native charges, which adds to the swelling of the polymer.   Presence of carvacrol alone in 
low amounts [F2–F4] caused a decrease in the swelling index. On the other hand, 
carvacrol in higher amounts [F5–F7], tetracycline [F8–F13], and combination of both   
[F14–F19] did not cause any detectable effect on swelling index for the patches. The 
patches did not show any appreciable changes in their shape and size during the 3-h 
soaking in simulated salivary solution.  
Physical characteristics of the patches 
The physical characteristics of selected patches are summarized in Table 3. The folding 
endurance was measured manually by folding the film repeatedly at a point until it broke. 
The breaking time was considered as the end point. The folding endurance test did not 
develop any visible cracks or breaks [>250 times], thus showing good film elasticity.   Preparation of Mucoadhesive Oral Patches Containing Tetracycline Hydrochloride and Carvacrol … 209 
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Fig. 5.   Swelling indexes of the patches. The average values are presented ± STD. 
Considering the fact that acidic or alkaline pH may cause irritation to the buccal mucosa 
and influence the degree of hydration of the polymers, the surface pH of the buccal films 
was determined to optimize both drug permeation and mucoadhesion. The surface pH of 
the patches was determined in order to investigate the possibility of any side effects in the 
oral cavity. As shown in Table 3, the average pH value is 6.31 ± 0.51 for various patches. 
This shows that there is no significant difference between the pH of the patches and the 
mouth pH [6.68 ± 0.55] [30]. 
Drug content in the formulations was uniform and the standard deviation did not exceed 
0.7% of the theoretical concentration. This indicates that the drug was dispersed uniformly 
throughout the films. The average thickness of the patches was 0.15 ± 0.05 mm. Weight 
variation was uniform in the patches with an average value of 0.05 ± 0.01 g.  
Physical appearance was good for all the prepared patches. Stability of the patches was 
tested over 6 months. All the prepared patches were stable in physical appearance, 
uniformity of weight, and thickness. The films did not exhibit any color changes during the 
storage period. Results showed that the decrease in drug content did not exceed 2%. This 
suggests that the stability was satisfactory for the drug and the patches during the storage 
period. 
Conclusions 
A novel mucoadhesive bilayered film consisting of ethyl cellulose as a backing layer and 
carbopol 934 as a matrix-forming layer was prepared using the casting method. 
Combination of tetracycline and carvacrol showed excellent activity against Candida 
albicans and the selected bacterial strains. Evidence of synergism between the two 210  R. M. Obaidat et al.:  
Sci Pharm. 2011; 79: 197–212 
components against Pseudomonas aeruginosa and Bacillus  cereus was shown and it 
needs further investigation. The prepared patches showed a sustained release action for 
more than 6 h, acceptable bioadhesion, and stability. The best suggested patch according 
to our results was F14 [0.01 g tetracycline and 1.1 mg carvacrol per 10 cm
2 of film] which 
contained the least effective concentrations of the two active components and the 
maximum delayed release and an acceptable mucoadhesion force. 
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